Fellow Sber Shelley Dpicks up on a discussion of billionaires stepping up to fund basic research originally from Forbes. The most unfortunate passage reads:
(Dr.) Melton landed enough money to start a separate lab, and he works on turning his stem line into insulin-producing cells to study where they go wrong in diabetics. But half his budget goes to redundant lab gear and overhead he wouldn’t need if it weren’t for the NIH rules against stem-cell funding. His stem-cell colleague at Harvard, M. Wiliam Lensch, uses only private funding from Harvard but worries about getting in trouble if he merely talks to NIH-funded peers in his lab.
As I’ve discussed before, the arbitrary restriction of federal funding to a small number of largely useless lines has wasted a ton of money and tremendous amounts of time. I wonder if the objective wasn’t even more insidious, through.